Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-CIRCUIT trial of uninterrupted dabigatran versus warfarin during atrial fibrillation ablation
NL-OMON42157Phase 4Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dabigatran and warfarin in Atrial fibrillation (AFib), sponsored by Boehringer Ingelheim. Started Jul 2015; status: active, not recruiting.
02
Drugs
dabigatranwarfarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON42157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42157.